Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Yin, Geng ^a   Wang, Ying ^a   Cen, Xiao Min ^a   Yang, Min ^a   Liang, Yan ^a   Xie, Qi Bing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; CASPASE 3; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN KINASE B; STAT PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL NUCLEUS; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFLAMMATION; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; UPREGULATION; WESTERN BLOTTING; CELL LINE; CYTOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELL LINE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPID PEROXIDATION; NF-KAPPA B; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924059258     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/460310     Document Type: Article

References (35)

1. G. S. Firestein, "Evolving concepts of rheumatoid arthritis," Nature, vol. 423, no. 6937, pp. 356-361, 2003.
2. H. Nakayama, T. Yaguchi, S. Yoshiya, and T. Nishizaki, "Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner," Rheumatology International, vol. 32, no. 1, pp. 151-157, 2012.
3. V. Badot, P. Durez, B. J. van den Eynde, A. Nzeusseu-Toukap, F. A. Houssiau, and B. R. Lauwerys, "Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines," Journal of Cellular and Molecular Medicine, vol. 15, no. 11, pp. 2335-2342, 2011.
4. J. Kurkó, T. Besenyei, J. Laki, T. T. Glant, K. Mikecz, and Z. Szekanecz, "Genetics of rheumatoid arthritis-a comprehensive review," Clinical Reviews in Allergy and Immunology, vol. 45, no. 2, pp. 170-179, 2013.
5. C. Perricone, F. Ceccarelli, and G. valesini, "An overview on the genetic of rheumatoid arthritis: a never-ending story," Autoimmunity Reviews, vol. 10, no. 10, pp. 599-608, 2011.
6. B. Bartok and G. S. Firestein, "Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis," Immunological Reviews, vol. 233, no. 1, pp. 233-255, 2010.
7. N. Bottini and G. S. Firestein, "Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors," Nature Reviews Rheumatology, vol. 9, no. 1, pp. 24-33, 2013.
8. A. Mor, S. B. Abramson, and M. H. Pillinger, "The fibroblastlike synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction," Clinical Immunology, vol. 115, no. 2, pp. 118-128, 2005.
9. M. E. Weinblatt, J. M. Kremer, A. D. Bankhurst et al., "A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate," The New England Journal of Medicine, vol. 340, no. 4, pp. 253-259, 1999.
10. M. J. Elliott, R. N. Maini, M. Feldmann et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," The Lancet, vol. 344, no. 8930, pp. 1105-1110, 1994.
11. G. R. Burmester, X. Mariette, C. Montecucco et al., "Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: theResearch inActiveRheumatoidArthritis (ReAct) trial," Annals of the Rheumatic Diseases, vol. 66, no. 6, pp. 732-739, 2007.
12. C. S. Mitsiades, N. Mitsiades, V. Poulaki et al., "Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications," Oncogene, vol. 21, no. 37, pp. 5673-5683, 2002.
13. J. R. Hwang, K. Jo, Y. Lee, B.-J. Sung, Y. W. Park, and J.-H. Lee, "Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation," Carcinogenesis, vol. 33, no. 1, pp. 77-83, 2012.
14. S. G. Pereira and F. Oakley, "Nuclear factor-kappaB1: regulation and function," International Journal of Biochemistry & Cell Biology, vol. 40, no. 8, pp. 1425-1430, 2008.
15. S. vallabhapurapu and M. Karin, "Regulation and function of NF-κB transcription factors in the immune system," Annual Review of Immunology, vol. 27, pp. 693-733, 2009.
16. J. Bondeson, B. Foxwell, F. Brennan, and M. Feldmann, "Defining therapeutic targets by using adenovirus: blocking NFkappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators," Proceedings of the National Academy of Sciences of theUnited States of America, vol. 96,no. 10,pp. 5668-5673, 1999.
17. J. Bondeson, S. Lauder, S. Wainwright et al., "Adenoviral gene transfer of the endogenous inhibitor IκBα into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor- κB-dependent," Journal of Rheumatology, vol. 34, no. 3, pp. 523-533, 2007.
18. S. S. Makarov, "NF-κB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction," Arthritis Research, vol. 3, no. 4, pp. 200-206, 2001.
19. T. Hettmann, J. DiDonato, M. Karin, and J. M. Leiden, "An essential role for nuclear factor κB in promoting double positive thymocyte apoptosis," Journal of Experimental Medicine, vol. 189, no. 1, pp. 145-157, 1999.
20. R. Bessho, K. Matsubara, M. Kubota et al., "Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor κB (NFkappaB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes," Biochemical Pharmacology, vol. 48, no. 10, pp. 1883-1889, 1994.
21. M. Grilli, M. Pizzi, M. Memo, and P. Spano, "Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation," Science, vol. 274, no. 5291, pp. 1383-1385, 1996.
22. V. N. Ivanov, R. K. Lee, E. R. Podack, and T. R. Malek, "Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF- κB," Oncogene, vol. 14, no. 20, pp. 2455-2464, 1997.
23. C. Abbadie, N. Kabrun, F. Bouali et al., "High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro," Cell, vol. 75, no. 5, pp. 899-912, 1993.
24. M. Trevisani, J. Siemens, S. Materazzi et al., "4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 33, pp. 13519-13524, 2007.
25. A. Ayala, M. F. Muñoz, and S. Argüelles, "Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal," Oxidative Medicine and Cellular Longevity, vol. 2014,Article ID 360438, 31 pages, 2014.
26. S. M. Plummer, K. A. Holloway, M. M. Manson et al., "Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NFkappaB activation via the NIK/IKK signalling complex," Oncogene, vol. 18, no. 44, pp. 6013-6020, 1999.
27. L. Burkly, C. Hession, L. Ogata et al., "Expression of relB is required for the development of thymic medulla and dendritic cells," Nature, vol. 373, no. 6514, pp. 531-536, 1995.
28. M. Carini, G. Aldini, and R. M. Facino, "Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins," Mass Spectrometry Reviews, vol. 23, no. 4, pp. 281-305, 2004.
29. Y.C. Awasthi,R. Sharma, J. Z. Cheng et al., "Role of 4-hydroxynonenal in stress-mediated apoptosis signaling," Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 219-230, 2003.
30. S. J. Chapple, X. Cheng, and G. E. Mann, "Effects of 4-hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease," Redox Biology, vol. 1, no. 1, pp. 319-331, 2013.
31. S. Dwivedi,A. Sharma, B. Patrick, R. Sharma, and Y. C. Awasthi, "Role of 4-hydroxynonenal and its metabolites in signaling," Redox Report, vol. 12, no. 1-2, pp. 4-10, 2007.
32. J. Alary, F. Guéraud, and J.-P. Cravedi, "Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways," Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 177-187, 2003.
33. I. Nakashima,W. Liu, A. A. Akhand et al., "4-Hydroxynonenal triggers multistep signal transduction cascades for suppression of cellular functions,"Molecular Aspects ofMedicine, vol. 24, no. 4-5, pp. 231-238, 2003.
34. Y. Yang, R. Sharma, A. Sharma, S. Awasthi, and Y. C. Awasthi, "Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling," Acta Biochimica Polonica, vol. 50, no. 2, pp. 319-336, 2003.
35. J. R. Roede and D. P. Jones, "Reactive species andmitochondrial dysfunction: mechanistic significance of 4-hydroxynonenal," Environmental and Molecular Mutagenesis, vol. 51, no. 5, pp. 380-390, 2010.